1型糖尿病亚组三年血糖轨迹:多中心CGM研究
这项多中心研究纳入1028例1型糖尿病成人,分析3441份纵向CGM谱,按年龄、CKD、β细胞功能、BMI和TyG三分位分层。结果显示高龄和CKD与血糖改善相关且不加重低血糖,严重β细胞衰竭限制血糖获益,提示需个体化目标。
要点
- 高龄和CKD患者纵向TIR改善且低血糖未加重。
- 严重β细胞衰竭削弱TIR改善和TBR降低。
- 亚组内CGM指标差异大,支持个体化血糖目标。
核心结论
- 高龄和CKD与纵向血糖改善相关且不加重低血糖,严重β细胞衰竭限制血糖获益,亚组内异质性大支持个体化目标。
研究设计与样本
- 多中心研究,纳入1028例1型糖尿病成人,贡献3441份纵向CGM谱,按年龄、CKD、β细胞功能、BMI和TyG三分位分层,用线性混合效应模型估计纵向变化。
主要发现
- 基线时,高龄、CKD、严重β细胞衰竭、较高BMI和最高TyG三分位亚组TAR(>180 mg/dL)更多(均P<0.05)。
- 严重β细胞衰竭还与更多TBR(<70 mg/dL)和更大血糖变异相关(均P<0.001)。
- 与年轻个体相比,高龄者TIR(70-180 mg/dL)改善相当(β=0.110;P=0.102),且维持更低TBR(3.5% vs 1.7%;P<0.001)。
- CKD组TIR显著改善(β=0.228;P=0.002)而无低血糖加重;严重β细胞衰竭减弱TIR改善(β=-0.119;P=0.025)和TBR降低(β=0.046;P<0.001)。
- 较高BMI和最高TyG三分位者绝对TIR更低,但最高TyG三分位者TIR改善更大(β=0.083;P=0.001)。
关键数值与推荐
- TAR定义为>180 mg/dL,TBR定义为<70 mg/dL,TIR定义为70-180 mg/dL。
临床怎么用
- 对高龄和CKD的1型糖尿病患者可预期血糖改善且低血糖风险不增加。
- 严重β细胞衰竭患者需关注血糖改善受限和低血糖风险。
- 应结合CGM轨迹和亚组特征制定个体化血糖目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine 3-year longitudinal trajectories of continuous glucose monitoring (CGM) metrics across subgroups at risk for suboptimal glycemic control among adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this multicenter study, 1,028 individuals contributed 3,441 longitudinal CGM profiles. Participants were stratified on the basis of age, chronic kidney disease (CKD), β-cell function, BMI, and triglyceride-glucose (TyG) tertile. Linear mixed-effects models were used to estimate subgroup differences in longitudinal changes. RESULTS: At baseline, there was more time spent with glucose above target range (>180 mg/dL), for the subgroups of older age, CKD, severe β-cell failure, higher BMI, and highest TyG tertile (all P < 0.05), while severe β-cell failure was additionally associated with more time spent with glucose below target range (time below range [TBR]) (<70 mg/dL), along with greater glycemic variability (all P < 0.001). In relation to younger individuals, for older adults, improvement in time spent with glucose in target range (time in range [TIR]) (70-180 mg/dL) was comparable (β = 0.110; P = 0.102) and lower TBR was maintained (3.5% vs. 1.7%, respectively; P < 0.001). Among the CKD group, significant improvement in TIR was seen (β = 0.228; P = 0.002) without exacerbation of hypoglycemia. Severe β-cell failure attenuated TIR improvement (β = -0.119; P = 0.025) and TBR reduction (β = 0.046; P < 0.001). Lower absolute TIR was seen for those with higher BMI and those in the highest TyG tertile. Greater TIR improvement was observed for those in the highest TyG tertile (β = 0.083; P = 0.001). CGM metrics varied widely within these subgroups. CONCLUSIONS: Older age and CKD were associated with longitudinal glycemic improvement without worsening of hypoglycemia, whereas severe β-cell failure limited glycemic gains; substantial within-group heterogeneity supports individualized glycemic targets informed by CGM trajectories in type 1 diabetes.
引用
- Yoo JH, Kim S, Park Y, et al. Three-Year Glycemic Trajectories in Subgroups With Type 1 Diabetes at Risk for Suboptimal Glycemic Control: A Multicenter Continuous Glucose Monitoring Study. Diabetes Care. 2026. PMID: 42747916. doi:10.2337/dc26-1039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。